Morepen Laboratories Share Price Today

Morepen Laboratories files first US ANDA for Sitagliptin tablets

Morepen Laboratories filed its first US ANDA for Sitagliptin Tablets USP in 25 mg, 50 mg and 100 mg strengths on September 25, 2026. The submission marks a strategic shift from API expertise to integrated finished dosage development and regulatory filing. Innovator product Januvia recorded worldwide sales of $1.604 billion in 2025, with key patents expiring in November 2026. Estimated approval timeline is 24–36 months, positioning Morepen for long-term partnerships rather than immediate market entry.

Morepen Labs shareholders approve Sanjay Suri elevation and medtech spin-off extension

All seven resolutions passed at Morepen Labs' 41st AGM held on September 26, 2026. Sanjay Suri elevated to Managing Director; Sushil Suri reappointed as Chairman & MD. Institutional investors opposed the medtech spin-off extension with 99.37% votes against. Final dividend of ₹0.20 per share declared for FY26.

Morepen Labs completes Phase 1 capacity expansion ahead of schedule

Morepen Laboratories completed Phase 1 of manufacturing expansion ahead of schedule. Installed reactor capacity for API and CDMO increased from 535 KL to 614 KL. Expansion supports scale-up of commercial CDMO supplies and existing API business. Move aligns with strategy to build scalable, globally compliant manufacturing platform.

Morepen Laboratories sets Sept 26 for 41st AGM; proposes ₹0.20 dividend

Morepen Laboratories schedules 41st AGM for September 26, 2026. Board proposes final dividend of ₹0.20 per equity share for FY26. Remote e-voting runs from September 23 to September 25, 2026. Sanjay Suri to be elevated to Managing Director effective July 1, 2026. Annual report web-link released for members without registered emails.

Morepen Laboratories files FY26 BRSR report, details sustainability metrics

Morepen Laboratories filed its FY26 BRSR report, disclosing a turnover of ₹16,766.7 crore. Capital expenditure on environmental technologies rose to 9.39% from 0% in FY25. Energy intensity improved to 272.43 GJ per crore INR of turnover. Scope 1 emissions decreased to 4,977.55 metric tonnes CO2 equivalent. Workforce includes 1,314 permanent employees and 1,755 workers.

Morepen Laboratories declares ₹0.20 per share final dividend for FY26

Morepen Laboratories declared a final dividend of ₹0.20 per equity share for FY26. The 41st AGM is scheduled for September 26, 2026 via VC/OAVM. Record date for dividend eligibility is set for September 19, 2026. Physical shareholders must update KYC by August 28, 2026 for electronic payment.